Paper37270486
Differential molecular pathway expression according to chemotherapeutic response in ovarian clear cell carcinoma.
Yin M and 4 others. BMC Womens Health, 2023. Cited by 3 papers, by iCite.
Cite this record
ConductScience Library. Differential molecular pathway expression according to chemotherapeutic response in ovarian clear cell carcinoma. Papers, record 37270486. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37270486
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Differential molecular pathway expression according to chemotherapeutic response in ovarian clear cell carcinoma.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Ovarian Neoplasms | Major topic |
| Female | |
| Humans | |
| Neoplasm Recurrence, Local | |
| Carcinoma, Ovarian Epithelial | |
| Biomarkers | |
| Phosphatidylinositol 3-Kinases |
Source PubMed
References63
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32651885 | Bevacizumab in recurrent ovarian cancer: could it be particularly effective in patients with clear cell carcinoma? | Clin Transl Oncol | 2021 | https://conductscience.org/library/papers/32651885 | PubMed |
| 2 | 33236151 | miR‑576‑3p overexpression enhances cisplatin sensitivity of ovarian cancer cells by dysregulating PD‑L1 and cyclin D1. | Mol Med Rep | 2021 | https://conductscience.org/library/papers/33236151 | PubMed |
| 3 | 35211759 | Molecular mechanisms of platinum‑based chemotherapy resistance in ovarian cancer (Review). | Oncol Rep | 2022 | https://conductscience.org/library/papers/35211759 | PubMed |
| 4 | 27794568 | Bevacizumab in Ovarian Cancer: State of the Art and Unanswered Questions. | Chemotherapy | 2017 | https://conductscience.org/library/papers/27794568 | PubMed |
| 5 | 36095166 | The Tumor Microenvironment of Clear-Cell Ovarian Cancer. | Cancer Immunol Res | 2022 | https://conductscience.org/library/papers/36095166 | PubMed |
| 6 | 31319139 | Low-dose triple drug combination targeting the PI3K/AKT/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinoma. | Cancer Lett | 2019 | https://conductscience.org/library/papers/31319139 | PubMed |
| 7 | 26053278 | CDK4/6 inhibitors in breast cancer. | Anticancer Drugs | 2015 | https://conductscience.org/library/papers/26053278 | PubMed |
| 8 | 31652965 | Understanding and Targeting Apoptotic Pathways in Ovarian Cancer. | Cancers (Basel) | 2019 | https://conductscience.org/library/papers/31652965 | PubMed |
| 9 | 25936818 | Broad targeting of resistance to apoptosis in cancer. | Semin Cancer Biol | 2015 | https://conductscience.org/library/papers/25936818 | PubMed |
| 10 | 34982265 | OSI-906 restores the sensitivity of ovarian clear cell carcinoma to cisplatin by targeting the IGF1R/AKT pathway. | Med Oncol | 2022 | https://conductscience.org/library/papers/34982265 | PubMed |
| 11 | 35622184 | Caveolin-1-ACE2 axis modulates xenobiotic metabolism-linked chemoresistance in ovarian clear cell carcinoma. | Cell Biol Toxicol | 2023 | https://conductscience.org/library/papers/35622184 | PubMed |
| 12 | 33168565 | Treatment of epithelial ovarian cancer. | BMJ | 2020 | https://conductscience.org/library/papers/33168565 | PubMed |
| 13 | 31046081 | ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†. | Ann Oncol | 2019 | https://conductscience.org/library/papers/31046081 | PubMed |
| 14 | 25341576 | Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the ovary. | Int J Gynecol Cancer | 2014 | https://conductscience.org/library/papers/25341576 | PubMed |
| 15 | 30217369 | Genomics to immunotherapy of ovarian clear cell carcinoma: Unique opportunities for management. | Gynecol Oncol | 2018 | https://conductscience.org/library/papers/30217369 | PubMed |
| 16 | 26675567 | Potential targets for ovarian clear cell carcinoma: a review of updates and future perspectives. | Cancer Cell Int | 2015 | https://conductscience.org/library/papers/26675567 | PubMed |
| 17 | 25519148 | Preclinical Efficacy for AKT Targeting in Clear Cell Carcinoma of the Ovary. | Mol Cancer Res | 2015 | https://conductscience.org/library/papers/25519148 | PubMed |
| 18 | 32948640 | Clear cell carcinoma of the ovary: a clinical and molecular perspective. | Int J Gynecol Cancer | 2021 | https://conductscience.org/library/papers/32948640 | PubMed |
| 19 | 18377417 | Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma. | Cancer Sci | 2008 | https://conductscience.org/library/papers/18377417 | PubMed |
| 20 | 31046082 | Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. | Ann Oncol | 2019 | https://conductscience.org/library/papers/31046082 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 37761986 | High Tumor-Infiltrating Lymphocyte Count Is Associated with Distinct Gene Expression Profile and Longer Patient Survival in Advanced Ovarian Cancer. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37761986 | PubMed |
| 37525667 | Fibroblast Growth Factor 11 (FGF11) Promotes Progression and Cisplatin Resistance Through the HIF-1α/FGF11 Signaling Axis in Ovarian Clear Cell Carcinoma. | Cancer Manag Res | 2023 | https://conductscience.org/library/papers/37525667 | PubMed |
Genes27
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37270486
GET https://conductscience.org/api/papers/v1/37270486/references?page=2